Veracyte Secures Medicare Coverage for Genomic Thyroid Cancer Test
January 09, 2012
Veracyte Secures Medicare Coverage for Genomic Thyroid Cancer Test
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Prospective Validation Confirms Sensitivity of Veracyte's Gene Expression Test for Thyroid Nodule Risk
June 27, 2012 / Pharmacogenomics Reporter - UnitedHealthcare Starting Coverage of Veractye's Thyroid Cancer MDx
March 8, 2013 / GenomeWeb Daily News - MDx/CDx Focus: Positive Data for Trastuzumab Emtansine; Veracyte Gets NY OK for Afirma Thyroid Dx
August 29, 2012 / Pharmacogenomics Reporter - Veracyte's Thyroid Cancer MDx Gets New York State OK
August 29, 2012 / GenomeWeb Daily News - European Researchers and Pharmas Launch Effort to Link Gene Markers to Diabetes, Personalize Drugs
February 29, 2012 / Pharmacogenomics Reporter